| Title |
Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, November 2012
|
| DOI | 10.1002/14651858.cd008079.pub2 |
| Pubmed ID | |
| Authors |
Kathrin Bauer, Michaela Rancea, Verena Roloff, Thomas Elter, Michael Hallek, Andreas Engert, Nicole Skoetz |
| Abstract |
Chronic lymphocytic leukaemia (CLL) accounts for 25% of all leukaemias and is the most common lymphoid malignancy in western countries. Standard treatments include mono- or polychemotherapies, usually combined with monoclonal antibodies such as rituximab or alemtuzumab. However, the impact of these agents remains unclear, as there are hints for increased risk of severe infections. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 17% |
| Germany | 1 | 17% |
| Mexico | 1 | 17% |
| Unknown | 3 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 83% |
| Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 189 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 2 | 1% |
| Colombia | 1 | <1% |
| France | 1 | <1% |
| Brazil | 1 | <1% |
| Russia | 1 | <1% |
| Croatia | 1 | <1% |
| Unknown | 182 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 23 | 12% |
| Researcher | 22 | 12% |
| Student > Bachelor | 21 | 11% |
| Student > Ph. D. Student | 19 | 10% |
| Other | 16 | 8% |
| Other | 37 | 20% |
| Unknown | 51 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 82 | 43% |
| Agricultural and Biological Sciences | 10 | 5% |
| Nursing and Health Professions | 9 | 5% |
| Biochemistry, Genetics and Molecular Biology | 8 | 4% |
| Psychology | 6 | 3% |
| Other | 22 | 12% |
| Unknown | 52 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 April 2013.
All research outputs
#7,721,215
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#8,672
of 11,842 outputs
Outputs of similar age
#56,330
of 192,725 outputs
Outputs of similar age from Cochrane database of systematic reviews
#176
of 245 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 11,842 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.9. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 192,725 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 245 others from the same source and published within six weeks on either side of this one. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.